August 16, 2023
1 min watch
Save
VIDEO: High-dose aflibercept demonstrates benefit in lengthening re-treatment interval
SEATTLE — In this video, Rishi P. Singh, MD, FASRS, discusses presentations from the ASRS annual meeting that discussed high-dose aflibercept for the treatment of neovascular age-related macular degeneration.
Baseline characteristics such as increased vision on study entry helped predict longer intervals of re-treatment, according to Singh, president of Martin North and South Hospitals and professor of ophthalmology at Cleveland Clinic Lerner College of Medicine.
“[Aflibercept] is showing us some benefits in 8 mg therapy. It demonstrated longer intervals of re-treatment,” Singh said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Singh reports consulting for Alimera, Apellis, Aviceda, Bausch + Lomb, EyePoint, Genentech, Iveric and Regeneron.